The Science of
Gubra enables you to progress your preclinical pharmacology development for metabolic disorders with more certainty than any other research partner
Benefit from our extensive NASH know-how and test your compound in our validated DIO mouse model of NASH.
Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.
Check out our novel rodent models of diabetic nephropathy and diabetic cardiomyopathy.
Principal Scientist, Head of In Vivo Pharmacology, Cardiovascular & Metabolic Diseases | MedImmune
MD, PhD, Director of Center for Diabetes Research | Gentofte Hospital, University of Copenhagen
Dr. Michael Mark
Vice President | Boeringer Ingelheim
Gubra now offers state-of-the art 3D imaging technologies to visualize pathogenesis and compound distribution in whole organs with single cell resolution.
See the visualization and read more
Find out more about the partner program between Boeringer Ingelheim Pharma and Gubra.